Back to search results

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

Abroad (travel likely)Recruiting

Conditions

HNSCC · NSCLC · Esophageal Cancer · Urothelial Carcinoma · Renal Cell Carcinoma · Squamous Cell Carcinoma of the Skin · Small Cell Bronchial Carcinomas

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany

    Contact: Study coordinator (Benjamin Frey, Dr.-Ing.) · benjamin.frey@uk-erlangen.de · +49 9131 85
    Contact: Study coordinator (Anna Donaubauer, M.Sc.) · anna-jasmina.donaubauer@uk-erlangen.de · +49 9131 85
    Contact: Principal Investigator (Markus Hecht, M.D.)
    Contact: Principal Investigator (Udo S Gaipl, Prof. Dr.)
    Contact: Principal Investigator (Rainer Fietkau, Prof. Dr.)
Study leads

  • Markus Hecht, PD Dr.

    Study Director

    Universitätsklinikum Erlangen, Department of Radiation Oncology

  • Udo S Gaipl, Prof. Dr.

    Principal Investigator

    Universitätsklinikum Erlangen, Department of Radiation Oncology

  • Rainer Fietkau, Prof. Dr.

    Study Chair

    Universitätsklinikum Erlangen, Department of Radiation Oncology

  • Benjamin Frey, PD Dr. Dr.

    Principal Investigator

    Universitätsklinikum Erlangen, Department of Radiation Oncology

View source on ClinicalTrials.gov(opens in a new tab)